Enrolment Ended for HONEST-PREPS

The enrollment of this many patients is a great achievement for everyone involved in the study. It shows the dedication and commitment by the participating local sites’ teams working in Intensive Care Units. The teams at the participating sites continuously enrolled patients, even during the difficult and challenging COVID-19 waves.

In February 2022, all participating sites were invited to participate in an EQA-panel organized by LAB-Net. The panel consisted of 10 swabs as samples that contain HAP/VAP related bacterial pathogens. LAB-Net provided to each laboratory an individual report on their performance together with the intended results.

Sites were also invited to participate in the seminar “Sampling and screening of patients for HAP/VAP diagnostics” organized by LAB-net. The seminar was given on 4 and 28 April 2022 and was attended by clinicians and laboratory workers. All attendees were awarded the certificate of attendance. Read more on LAB-Net’s involvement in this trial in this update.

For the remainder of the study, the sites will focus on final data entry until 31 May 2022. The data cleaning process is already ongoing. Data lock and site close out procedures will follow.

ECRAID-Base POS-VAP study

Sites that performed well in the HONEST-PREPS study have been invited to continue in ECRAID-Base Perpetual Observational Study into Ventilator Associated Pneumonia (POS-VAP) with the prospect of joining future Randomized Controlled Trials. The team at CHU Limoges will be executing the POS-VAP study and will continue the collaboration with HONEST-PREPS sites.

The primary objective of ECRAID-Base’s POS-VAP is to provide an infrastructure capable of rapidly implementing randomized controlled trials and other clinical trials related to prevention, diagnosis or treatment of VAP in ICUs. The secondary objectives include descriptive analyses related to patient characteristics, complications, outcome and risk factors.

About HONEST-PREPS

The aim of the HONEST-PREPS is to set up an infrastructure to prospectively enroll patients at risks of HAP/VAP in the ICU. Collected data will be used to inform future diagnostic, preventative and therapeutic trials. In addition to capturing HAP/VAP episodes in a timely manner, HONEST-PREPS will determine the incidence, microbiological etiology (including antibiotic resistance), management and outcome of HAP/VAP in the ICU.